Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]McLeod DS, Sawka AM, Cooper DS: Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet 381:1046-1057 (2013)

  • [2]The People’s Goverment of Beijing Municipality: The report of health and population health in Beijing (2011)

  • [3]Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428 (1994)

  • [4]Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST: Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83:1012-1021 (1998)

  • [5]Haugen BR, Kane MA: Approach to the thyroid cancer patient with extracervical metastases. J Clin Endocrinol Metab 95:987-993. (2010)

  • [6]Nixon IJ, Whitcher MM, Palmer FL, Tuttle RM, Shaha AR. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 22:884-889 (2012)

  • [7]Turner HE, Harris AL, Melmed S, Wass JA: Angiogenesis in endocrine tumors. Endocr Rev 24:600-632 (2003)

  • [8]Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404 (2003)

  • [9]Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379 (2005)

  • [10]Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246:466-470; discussion 470-461 (2007)

  • [11]Huber MA, Kraut N, Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548-558 (2005)

  • [12]Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457 (2003)

  • [13]Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65:4238-4245 (2005)

  • [14]Kim TY, Kim WB, Song JY, Rhee YS, Gong G. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 63:588-593 (2005)

  • [15]Xing M: Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13:184-199 (2013)

  • [16]Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A: ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21:3226-3235 (2003)

  • [17]Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268:884-886 (1995)

  • [18]Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 93:611-618 (2008)

  • [19]Liu Z, Hou P, Ji M, Guan H, Studeman K. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93:3106-3116 (2008)

  • [20]Nikiforov YE: RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13:3-16 (2002)

  • [21]Al-Nedawi K, Meehan B, Rak J: Microvesicles: messengers and mediators of tumor progression. Cell Cycle 8:2014-2018 (2009)

  • [22]Castellone MD, De Falco V, Rao DM, Bellelli R, Muthu M: The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res 69:1867-1876 (2009)

  • [23]Miyagi E, Braga-Basaria M, Hardy E, Vasko V, Burman KD. Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Mol Carcinog 41:98-107 (2004)

  • [24]Soman NR, Correa P, Ruiz BA, Wogan GN: The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci U S A 88:4892-4896 (1991)

  • [25]Chen BK, Ohtsuki Y, Furihata M, Takeuchi T, Iwata J: Overexpression of c-Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathologic stage. Pathol Res Pract 195:427-433 (1999)

  • [26]Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E: PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma (corrected). Science 289:1357-1360 (2000)

  • [27]Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 88:4440-4445 (2003)

  • [28]Eberhardt NL, Grebe SK, McIver B, Reddi HV: The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol 321:50-56 (2010)

  • [29]Shevde LA, Welch DR: Metastasis suppressor pathways--an evolving paradigm. Cancer Lett 198:1-20 (2003)

  • [30]Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3:55-63 (2003)

  • [31]Horak CE, Lee JH, Marshall JC, Shreeve SM, Steeg PS: The role of metastasis suppressor genes in metastatic dormancy. APMIS 116:586-601 (2008)

  • [32]Zafon C, Obiols G, Castellvi J, Tallada N, Galofre P: nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:3975-3980 (2001)

  • [33]Arai T, Yamashita T, Urano T, Masunaga A, Itoyama S: Preferential reduction of nm23-H1 gene product in metastatic tissues from papillary and follicular carcinomas of the thyroid. Mod Pathol 8:252-256 (1995)

  • [34]Scheumman GF, Hoang-Vu C, Cetin Y, Gimm O, Behrends J: Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J Clin Endocrinol Metab 80:2168-2172 (1995)

  • [35]von Wasielewski R, Rhein A, Werner M, Scheumann GF, Dralle H: Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 57:2501-2507 (1997)

  • [36]Ringel MD, Hardy E, Bernet VJ, Burch HB, Schuppert F: Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells. J Clin Endocrinol Metab 87:2399 (2002)

  • [37]Stathatos N, Bourdeau I, Espinosa AV, Saji M, Vasko VV: KiSS-1/G protein-coupled receptor 54 metastasis suppressor pathway increases myocyte-enriched calcineurin interacting protein 1 expression and chronically inhibits calcineurin activity. J Clin Endocrinol Metab 90:5432-5440 (2005)

  • [38]Espinosa AV, Shinohara M, Porchia LM, Chung YJ, McCarty S: Regulator of calcineurin 1 modulates cancer cell migration in vitro. Clin Exp Metastasis 26:517-526 (2009)

  • [39]Ito Y, Yoshida H, Uruno T, Nakano K, Takamura Y: KAI1 expression in thyroid neoplasms: its linkage with clinicopathologic features in papillary carcinoma. Pathol Res Pract 199:79-83 (2003)

  • [40]Arai T, Watanabe M, Onodera M, Yamashita T, Masunaga A: Reduced nm 23-H1 messenger RNA expression in metastatic lymph nodes from patients with papillary carcinoma of the thyroid. Am J Pathol 142:1938-1944 (1993)

  • [41]Okubo T, Inokuma S, Takeda S, Itoyama S, Kinoshita K: Expression of nm23-H1 gene product in thyroid, ovary, and breast cancers. Cell Biophys 26:205-213 (1995)

  • [42]Lee JH, Welch DR: Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 57:2384-2387 (1997)

  • [43]Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM: KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 88:1731-1737 (1996)

  • [44]Pallante P, Visone R, Croce CM, Fusco A: Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Endocr Relat Cancer 17: F91-104 (2010)

  • [45]Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297 (2004)

  • [46]Zhang X, Mao H, Lv Z: MicroRNA role in thyroid cancer pathogenesis. Front Biosci (Landmark Ed)18:734-739 (2013)

  • [47]Zhang X, Li M, Zuo K, Li D, Ye M: Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/beta-catenin signaling. J Clin Endocrinol Metab 98: E1305-1313 (2013)

  • [48]Mazeh H, Mizrahi I, Halle D, Ilyayev N, Stojadinovic A: Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid 21:111-118 (2011)

  • [49]Gao Y, Wang C, Shan Z, Guan H, Mao J: miRNA expression in a human papillary thyroid carcinoma cell line varies with invasiveness. Endocr J 57:81-86 (2010)

  • [50]Chou CK, Chen RF, Chou FF, Chang HW, Chen YJ: miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid 20:489-494 (2010)

  • [51]Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature 410:37-40 (2001)

  • [52]Kondo T, Ezzat S, Asa SL: Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292-306 (2006)

  • [53]Xing M: Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am 41:1135-1146, ix (2008)

  • [54]Murugan AK, Xing M: Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 71:4403-4411 (2011)

  • [55]Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA: B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A 107:10649-10654 (2010)

  • [56]Nucera C, Lawler J, Parangi S: BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res 71:2417-2422 (2011)

  • [57]Liang H, Zhong Y, Luo Z, Huang Y, Lin H: Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis. Int J Biol Markers 25:38-45 (2010)

  • [58]Wang X, Chao L, Zhen J, Chen L, Ma G: Phosphorylated c-Jun NH2-terminal kinase is overexpressed in human papillary thyroid carcinomas and associates with lymph node metastasis. Cancer Lett 293:175-180 (2010)

  • [59]Cass LA, Meinkoth JL: Ras signaling through PI3K confers hormone-independent proliferation that is compatible with differentiation. Oncogene 19:924-932 (2000)

  • [60]Kimura T, Dumont JE, Fusco A, Golstein J: Insulin and TSH promote growth in size of PC Cl3 rat thyroid cells, possibly via a pathway different from DNA synthesis: comparison with FRTL-5 cells. Eur J Endocrinol 140:94-103 (1999)

  • [61]Saito J, Kohn AD, Roth RA, Noguchi Y, Tatsumo I: Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH)3 kinase-dependent Akt-mediated signaling. Thyroid 11:339-351 (2001)

  • [62]De Vita G, Berlingieri MT, Visconti R, Castellone MD, Viglietto G: Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects. Cancer Res 60:3916-3920 (2000)

  • [63]Vasko V, Saji M, Hardy E, Kruhlak M, Larin A: Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 41:161-170 (2004)

  • [64]Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A: Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69:4885-4893 (2009)

  • [65]Suzuki H, Willingham MC, Cheng SY: Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 12:963-969 (2002)

  • [66]Wiseman SM, Griffith OL, Gown A, Walker B, Jones SJ: Immunophenotyping of thyroid tumors identifies molecular markers altered during transformation of differentiated into anaplastic carcinoma. Am J Surg 201:580-586 (2011)

  • [67]Sastre-Perona A, Santisteban P: Role of the wnt pathway in thyroid cancer. Front Endocrinol (Lausanne)3:31 (2012)

  • [68]Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789 (1995)

  • [69]Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S: Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem 279:54610-54619 (2004)

  • [70]Pacifico F, Leonardi A: Role of NF-kappaB in thyroid cancer. Mol Cell Endocrinol 321:29-35 (2010)

  • [71]Burrows N, Resch J, Cowen RL, von Wasielewski R, Hoang-Vu C: Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas. Endocr Relat Cancer 17:61-72 (2010)

  • [72]Scarpino S, Cancellario d’Alena F, Di Napoli A, Pasquini A, Marzullo A: Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol 202:352-358 (2004)

  • [73]Zhang J, Gill A, Atmore B, Johns A, Delbridge L: Upregulation of the signal transducers and activators of transcription 3 (STAT3) pathway in lymphatic metastases of papillary thyroid cancer. Int J Clin Exp Pathol 4:356-362 (2011)

  • [74]Shook D, Keller R: Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech Dev 120:1351-1383 (2003)

  • [75]Tsuji T, Ibaragi S, Hu GF: Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 69:7135-7139 (2009)

  • [76]Zhang Z, Liu ZB, Ren WM, Ye XG, Zhang YY: The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. Int J Mol Med 30:856-862 (2012)

  • [77]Thiery JP Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454 (2002)

  • [78]Brabant G, Hoang-Vu C, Cetin Y, Dralle H, Scheumann G: E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res 53:4987-4993 (1993)

  • [79]Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG: Methylation patterns of the E-cadherin 5’ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 275:2727-2732 (2000)

  • [80]Miettinen M, Franssila K, Lehto VP, Paasivuo R, Virtanen I: Expression of intermediate filament proteins in thyroid gland and thyroid tumors. Lab Invest 50:262-270 (1984)

  • [81]Bogenrieder T, Herlyn M: Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22:6524-6536 (2003)

  • [82]Peinado H, Lavotshkin S, Lyden D: The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 21:139-146 (2011)

  • [83]Guarino V, Castellone MD, Avilla E, Melillo RM: Thyroid cancer and inflammation. Mol Cell Endocrinol 321:94-102 (2010)

  • [84]Muzza M, Degl’Innocenti D, Colombo C, Perrino M, Ravasi E: The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol (Oxf)72:702-708 (2010)

  • [85]French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP: Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab 95:2325-2333 (2010)

  • [86]Ginestra A, Monea S, Seghezzi G, Dolo V, Nagase H: Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem 272:17216-17222 (1997)

  • [87]Muralidharan-Chari V, Clancy J, Plou C, Romao M, Chavrier P: ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol 19:1875-1885 (2009)

  • [88]Colombo M, Raposo G, Thery C: Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 30:255-289 (2014)

  • [89]Peinado JM, Leao C: Nicolau van Uden, a life with yeasts (1921-1991). IUBMB Life 64:556-560 (2012)

  • [90]Hood JL, San RS, Wickline SA: Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res 71:3792-3801 (2011)

  • [91]Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR: Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 151:1542-1556 (2012)

  • [92]Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L: Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:1470-1476 (2008)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2016Article

Molecular mechanisms in differentiated thyroid cancer

Jing Xie 1, Youben Fan 1,*, Xiaoping Zhang 2,3
Affiliations
Article Info

1 Center of Thyroid and Parathyroid, Department of General Surgery, Shanghai Sixth People’s Hospital, Shanghai Jiaotong University of Medicine, Shanghai, China

2 Department of Nuclear Medicine, Shanghai 10th People’s Hospital, Tongji University School of Medicine, Shanghai, China

3 Institute of Intervention Vessel, Tongji University, North Zhongshan Road, Shanghai, China

Abstract

Thyroid cancer is a common endocrine malignancy. The tumorigenesis of thyroid tumours has been identified in recent years, including numerous genetic alterations and several major signalling pathways. However, the molecular mechanisms involved in thyroid cancer metastasis remain controversial. Studies in thyroid cancer metastasis suggested that reactivation of several pathways, including epithelial to mesenchymal transition and microenvironment change, may be involved in thyroid cancer migration. The previously identified thyroid oncogenes, BRAF, RET/PTC and Ras, play important roles in regulating the metastatic process. Here, we review the recent knowledge eon molecular mechanisms involved in thyroid cancer metastasis.

Keywords

  • hyroid Cancer
  • Lymphaticand Distant Metastasis
  • Oncogenes
  • MicroRNA

References